Pyxis Oncology, Inc.
As of Oct 22, 2026, Pyxis Oncology is in Stage 3, the topping phase, now in week 2 (since Oct 14, 2026). It closed at $1.71, 68.0% below its 52-week high and below its 200-day average, which is falling.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is PYXS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PYXS among Biotechnology367th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …367 | PYXS | Stage 3 · wk 2 | 22 | −46.9% |
Pyxis Oncology: quick answers
What stage is Pyxis Oncology in?
As of Oct 22, 2026, Pyxis Oncology (PYXS) is in Stage 3, the topping phase. It entered Stage 3 on Oct 14, 2026 and is in week 2. What the four stages mean
Is Pyxis Oncology in an uptrend?
Its uptrend has stalled. Pyxis Oncology is in Stage 3, the topping phase that follows an advance. It trades 20.7% below its 200-day average, which is falling.
How far is Pyxis Oncology from its 52-week high?
Pyxis Oncology closed at $1.71 on Oct 22, 2026, 68.0% below its 52-week high of $5.34. Its 52-week low is $1.06.
How has Pyxis Oncology performed over the past year?
As of Oct 22, 2026, Pyxis Oncology is down 52.2% over the past year and up 48.7% so far in 2026.
Which sector and industry is Pyxis Oncology in?
Pyxis Oncology is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.